This review aims to underline the interrelation between high-risk HPV oncoproteins and PD-1/PD-L1 in the pathogenesis of cervical cancer, which could reinforce the role of PD-1/PD-L1 inhibitors as one of the main therapies for the management of HPV-positive human carcinomas including cervical. This evidence concerns the gene PDCD1 and cervical carcinoma.